Cryolife (NYSE:CRY) Upgraded to “Strong-Buy” by ValuEngine

ValuEngine upgraded shares of Cryolife (NYSE:CRY) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday morning, ValuEngine reports.

CRY has been the subject of several other research reports. TheStreet lowered Cryolife from a b- rating to a c+ rating in a research report on Wednesday, May 22nd. Canaccord Genuity set a $35.00 target price on Cryolife and gave the stock a buy rating in a research report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $31.91.

Shares of CRY traded up $0.76 during mid-day trading on Thursday, hitting $29.59. The stock had a trading volume of 18,157 shares, compared to its average volume of 176,270. The company has a market cap of $1.02 billion, a PE ratio of 112.96 and a beta of 0.65. The company’s fifty day simple moving average is $27.28 and its two-hundred day simple moving average is $29.01. The company has a quick ratio of 3.82, a current ratio of 5.03 and a debt-to-equity ratio of 0.83. Cryolife has a fifty-two week low of $23.99 and a fifty-two week high of $36.05.



Cryolife (NYSE:CRY) last issued its earnings results on Tuesday, July 30th. The medical equipment provider reported $0.11 EPS for the quarter, topping the consensus estimate of $0.08 by $0.03. The company had revenue of $71.14 million during the quarter, compared to analyst estimates of $70.79 million. Cryolife had a return on equity of 3.85% and a net margin of 0.87%. The business’s revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. Equities analysts expect that Cryolife will post 0.29 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in CRY. BNP Paribas Arbitrage SA boosted its position in Cryolife by 1,945.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,404 shares of the medical equipment provider’s stock valued at $216,000 after purchasing an additional 7,042 shares during the period. SG Americas Securities LLC boosted its position in Cryolife by 205.4% during the 1st quarter. SG Americas Securities LLC now owns 12,707 shares of the medical equipment provider’s stock valued at $371,000 after purchasing an additional 8,546 shares during the period. Rhumbline Advisers boosted its position in Cryolife by 0.6% during the 1st quarter. Rhumbline Advisers now owns 100,456 shares of the medical equipment provider’s stock valued at $2,930,000 after purchasing an additional 612 shares during the period. Comerica Bank boosted its position in Cryolife by 3.1% during the 1st quarter. Comerica Bank now owns 33,816 shares of the medical equipment provider’s stock valued at $1,031,000 after purchasing an additional 1,020 shares during the period. Finally, Texas Permanent School Fund boosted its position in Cryolife by 3.9% during the 1st quarter. Texas Permanent School Fund now owns 23,126 shares of the medical equipment provider’s stock valued at $675,000 after purchasing an additional 870 shares during the period. Institutional investors and hedge funds own 70.70% of the company’s stock.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Read More: Most Active Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.